-
Signature
-
By: /s/ Jo Chen, as Attorney-in-Fact for Eric Venker
-
Stock symbol
-
ROIV
-
Transactions as of
-
Oct 9, 2025
-
Transactions value $
-
-$55,514
-
Form type
-
4
-
Date filed
-
10/14/2025, 09:00 PM
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Venker Eric |
President & Immunovant CEO |
C/O ROIVANT SCIENCES LTD., 7TH FLOOR, 50 BROADWAY, LONDON, UNITED KINGDOM |
By: /s/ Jo Chen, as Attorney-in-Fact for Eric Venker |
2025-10-14 |
0001801917 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
ROIV |
Common Shares |
Options Exercise |
$1.66M |
+105K |
+6.97% |
$15.85 |
1.61M |
Oct 9, 2025 |
Direct |
|
| transaction |
ROIV |
Common Shares |
Sale |
-$1.71M |
-105K |
-6.52% |
$16.30 |
1.5M |
Oct 9, 2025 |
Direct |
F1 |
| transaction |
ROIV |
Common Shares |
Options Exercise |
$329K |
+20.7K |
+1.38% |
$15.85 |
1.53M |
Oct 13, 2025 |
Direct |
|
| transaction |
ROIV |
Common Shares |
Sale |
-$337K |
-20.7K |
-1.36% |
$16.25 |
1.5M |
Oct 13, 2025 |
Direct |
F1 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
| transaction |
ROIV |
Stock Option (Right to Buy) |
Options Exercise |
$0 |
-105K |
-10.74% |
$0.00 |
872K |
Oct 9, 2025 |
Common Stock |
105K |
$15.85 |
Direct |
F2 |
| transaction |
ROIV |
Stock Option (Right to Buy) |
Options Exercise |
$0 |
-20.7K |
-2.38% |
$0.00 |
851K |
Oct 13, 2025 |
Common Stock |
20.7K |
$15.85 |
Direct |
F2 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: